OncoMatch/Clinical Trials/NCT05620628
Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)
Is NCT05620628 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Durvalumab and Savolitinib for stomach cancer, adenocarcinoma.
Treatment: Durvalumab · Savolitinib — For patients who failed primary chemotherapy with MET amplification, The efficacy and safety of the chemotherapy are evaluated by using dervalumab and saboritinib in combination.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Biomarker criteria
Required: MET amplification (copy number 4 or higher by local NGS)
MET amplification by local NGS (The NGS result of the implementation agency is defined as copy number 4 or higher, which is the standard for amplification)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy
have progressed during or after 1st or 2nd chemotherapy treatment
Cannot have received: MET inhibitor
Any previous treatment with MET inhibitors
Lab requirements
Blood counts
Haemoglobin ≥9.0 g/dL (within 2 weeks of registration transfusion permitted); ANC ≥ 1.5 x 10^9/L; Platelet count ≥100 x 10^9/L (within 2 weeks of registration transfusion permitted)
Kidney function
Serum creatinine ≤1.5 x institutional ULN; Glomerular filtration rate < 45 mL/min as assessed by standard methodology at the investigating centre
Liver function
ALT and AST ≤2.5 x ULN with TBL≤ 1x ULN OR TBL >1ULN-≤1.5x ULN with ALT and AST ≤ 1x ULN
Cardiac function
Mean QT interval corrected for heart rate (QTc) ≥ 470 ms calculated from 3 electrograms (ECGs) using Friderecia's correction
Patients must have acceptable bone marrow, liver and renal function measured within 28 days prior to administration of study treatment as defined below: * Haemoglobin ≥9.0 g/dL (within 2 weeks of registration transfusion permitted) * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L * Platelet count ≥100 x 109/L (within 2 weeks of registration transfusion permitted) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x the upper limit of normal (ULN) with TBL≤ 1x ULN OR TBL >1ULN-≤1.5x ULN with ALT and AST ≤ 1x ULN * Serum creatinine ≤1.5 x institutional ULN * Glomerular filtration rate < 45 mL/min as assessed by standard methodology at the investigating centre
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify